Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-29

FDA Approved: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Solco Healthcare US, LLC)

View source ↗

Summary

The FDA approved a supplemental application for the generic fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide from Solco Healthcare US, LLC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Olmesartan Medoxomil and Hydrochlorothiazide (olmesartan medoxomil; hydrochlorothiazide)

Snippet

SUPPL AP for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE)